Summary Information:
NeuBase Therapeutics Inc. Common Stock
NASDAQ:NBSE


email
admin@troach.net
Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net

NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.


NeuBase Therapeutics Inc. Common Stock
Exchange: NASDAQ
Symbol: NBSE
SEC CIK: 0001173281
Phone: 6464501790
700 TECHNOLOGY DRIVE
PITTSBURGH PA 15219

CEO: Dietrich Stephan
Price when page updated: 0.66 Date: 2023-12-01
Company Website:
www.neubasetherapeutics.com

_Description: NeuBase Therapeutics Inc. is accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as appropriate, to resolve causal genetic defects in living systems. NeuBase's designer PATrOLâ„¢ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.

IPO YEAR:

Sector:
Health Care
Industry:
Biotechnology: Pharmaceutical Preparations
ADRTSO:

MarketCap:
2461276.00
Beta:
1.572317389320158
52 Week High:
12.89
52 Week Low:
2.52
52 Week Change:
-0.6011004126547455
Short Interest:

Short Date:

Shares Outstanding:
32725934
Dividend Rate:
0
Dividend Yield:
8.13%
ExDividend Date:

Latest EPS:

Latest EPS Date:
27 Oct 2022
Float:
0
return on Equity:
-99.00%
Consensus EPS:

Number Of Estimates:

EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
$4.564B
ttmEPS:
0
Revenue:
$25.476B
Gross Profit:

Cash:

Debt:

Institution Percent:
60.20%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
0.07%
Return on Assets:
4.50%
Return on Capital:

Profit Margin:
6.80%
Price to Sales:
3.26
Price To Book:
-
Short Ratio:
2.17
PE Ratio:
0
Employees:
15
1Y Guesstimate
N/A:N/A:N/A




__The following are links to various summary and news pages for
__NeuBase Therapeutics Inc. Common Stock [ NBSE ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX




Page design by: TRoach
Page Last Updated: 2023-12-01